Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats.
Samuel CharlesRicarda SüssenbergerTerry SettjeCatherine E LangstonChantal LainessePublished in: Journal of veterinary internal medicine (2023)
Daily PO molidustat administration may stimulate a clinically relevant erythropoietic response in anemic cats with CKD. This HIF-PH inhibitor may be an alternative for managing anemia in cats compared to recombinant EPO treatment.